Tao Wang

6PUBLICATIONS
11CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 14, 2024
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.

Caroline Taylor, Kamai M Patterson, Devira Friedman

|May 28, 2022
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Tao Wang, Desirée Denman, Silvia M Bacot

|Nov 13, 2021
IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses.

Taylor A Harper, Silvia M Bacot, Christie Jane Fennell

|Dec 02, 2020
Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy.

Silvia M Bacot, Taylor A Harper, Rebecca L Matthews

|Nov 28, 2019
Defining the right diluent for intravenous infusion of therapeutic antibodies.

Shen Luo, Keisha Melodi McSweeney, Tao Wang

|Dec 15, 2018
BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways.

Peng Yue, Taylor Harper, Silvia M Bacot

Pageof 1

Frequent Collaborators

3 joint publications

Taylor Harper

2 joint publications

Silvia M Bacot

2 joint publications

Gerald M Feldman

1 joint publications

Peng Yue